

Strides receives USFDA approval for Ethosuximide Softgel Capsules

**Softgel franchise now comprises of 10 approved products in the US
To be launched immediately by Strides Pharma Inc. in the US market**

Bangalore, 20 February 2019 Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for ***Ethosuximide Softgel Capsules USP, 250 mg*** from the United States Food & Drug Administration (USFDA). The product was approved in the first review cycle by the USFDA in **less than 10 months of filing under the GDUFA II regime**. The product is a generic version of Zarontin Capsules, 250 mg, of Pfizer Inc.

Strides specializes in softgel domain and is a global leader in the Rx space. Strides now has a large portfolio of softgel products which now comprises of 10 approved products for the US markets along with a strong product pipeline. Ethosuximide Softgel Capsules is part of Strides niche and small volume product portfolio with limited competition in the US market. According to IQVIA MAT data, the US market for Ethosuximide Softgel Capsules USP, 250 mg is approximately US\$ 10 Mn. As part of its portfolio maximization strategy, Strides will also commercialize the product in other geographies leveraging its vast footprint in other regulated markets.

The product will be manufactured at flagship facility in Bangalore and will be marketed by Strides Pharma Inc. in the US market.

The company has 86 cumulative ANDA filings with USFDA of which 57 ANDAs have been approved including 13 approvals received in FY 19.

About Ethosuximide Softgel Capsule

Ethosuximide Softgel capsule is an anti-epileptic medication to control brief, sudden loss of consciousness and uncontrolled jerking movements in children and adults.

About Strides

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical Company headquartered in Bangalore, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India- Bangalore (two sites), Pondicherry and Chennai, Singapore, Italy- Milan, and Kenya- Nairobi. The Company focusses on “difficult to manufacture” products that are sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com

For further information, please contact:

Strides

Badree Komandur,
Executive Director - Finance
+91 80 6784 0747

Investor Relations:

Kannan. N: +91 98450 54745
Vikesh Kumar: +91 80 6784 0827
Sandeep Baid : +91 80 6784 0791
Email: Sandeep.baid@strides.com

Strides Pharma Science Limited

(Formerly Strides Shasun Limited)
CIN : L24230MH1990PLC057062
Regd. Office: 201, 'Devavrata', Sector - 17,
Vashi, Navi Mumbai - 400 703
Corp. Office: Strides House,
Bannerghatta Road, Bangalore - 560076

PR Consultancy

Fortuna PR
K Srinivas Reddy: +91 90005 27213
srinivas@fortunapr.com

K Priya: +91 95354 25418
priya@fortunapr.com